As part of our on-going coverage on new cancer treatments, Oncology Associates produced a new video on the recently approved FDA cancer treatment Zydelig (Idelalisib).
Developed by Gilead, Zydelig is a targeted cancer drug that treats patients who have specific types of blood cancers like leukemia and lymphoma that have relapsed. These types of cancers include chronic lymphocytic leukemia (CLL), as well as for follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma.
How Zydelig Treatment Works
In this new video, oncologist discusses how the Zydelig treatment works as a targeted therapy, as well as what types of side effects this treatment may cause.
A targeted therapy involve certain cancer drugs that seek to target and destroy specific cancer causing cells such as specific proteins or gene mutations that can proliferate the growth of many types of cancers.
While targeted therapy is considered a type of chemotherapy treatment, it works differently, as it strives to cause less harm to healthy cells. As a result, these types of treatments generally have different types of side effects from standard chemo.
Learn more about Zydelig (Idelalisib) and how this cancer treatment works.
